In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on SELLAS Life Sciences Group Inc (SLS – Research Report), with a price target of $5. The company’s shares opened today at $1.77, close to its 52-week low of $0.80.
“Sellas presented additional positive data from the P2b triple negative breast cancer (TNBC) subgroup study of nelipepimut-S vaccine (NeuVax, NPS) at the San Antonio Breast Cancer Symposium.”
According to TipRanks.com, McCarthy is a 1-star analyst with an average return of -1.8% and a 34.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as ContraVir Pharmaceuticals Inc, Sonoma Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for SELLAS Life Sciences Group Inc with a $9 average price target.
Based on SELLAS Life Sciences Group Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $781K. In comparison, last year the company had a GAAP net loss of $6.08 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutic for a broad range of indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. The company was founded on April 3, 2006 and is headquartered in New York, NY.